AustralieFrV1, Main, Exploration, bibRecord, 00A513

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg

Identifieur interne : 00A513 ( Main/Exploration ); précédent : 00A512; suivant : 00A514

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg

Auteurs : John R. Zalcberg [Australie] ; Jaap Verweij [Pays-Bas] ; Paolo G. Casali [Italie] ; Axel Le Cesne [France] ; Peter Reichardt [Allemagne] ; Jean-Yves Blay [France] ; Marcus Schlemmer [Allemagne] ; Martine Van Glabbeke [Belgique] ; Michelle Brown [Belgique] ; Ian R. Judson [Royaume-Uni]

Source :

European journal of cancer : (1990) [ 0959-8049 ] ; 2005.

RBID : Pascal:05-0400757

Descripteurs français

Pascal (Inist)
- Imatinib, Pronostic, Homme, Intestin, Stroma, Crossing over, Dose journalière, Protein-tyrosine kinase, Inhibiteur enzyme, Cancérologie, Pharmacologie, Anticancéreux, Tumeur stromale gastrointestinale.
Wicri :
- topic : Homme, Pharmacologie.

English descriptors

KwdEn :
- Antineoplastic agent, Cancerology, Crossing over, Daily dose, Enzyme inhibitor, Gastrointestinal stromal tumor, Gut, Human, Imatinib, Pharmacology, Prognosis, Protein-tyrosine kinase, Stroma.

Abstract

In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumours (GIST) were randomised to receive 400 or 800 mg of imatinib daily. An increase in progression free survival (PFS) was demonstrated for patients randomised to the high-dose arm. Patients randomised to low-dose could cross-over to high-dose upon progression. We evaluated the feasibility, safety and efficacy of this policy. Of the 241 patients available for follow-up, 133 patients (55%) crossed over to high-dose imatinib according to the protocol. Of these patients, 92% had not had a prior dose reduction. The cumulative incidence of subsequent dose reductions after cross-over was 17% after six months with 51% discontinuing therapy without requiring a dose reduction. The extent of anaemia and fatigue increased significantly after cross-over, whilst neutropenia was less severe than during low-dose treatment. Objective responses after cross-over included three patients (2%) with a partial response and 36 (27%) with stable disease. The median PFS after cross-over was 81 days, although 18.1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy.

Affiliations:

Allemagne, Australie, Belgique, France, Italie, Pays-Bas, Royaume-Uni
Angleterre, Auvergne-Rhône-Alpes, Bavière, Berlin, District de Haute-Bavière, Grand Londres, Hollande-Méridionale, Lombardie, Rhône-Alpes, Région de Bruxelles-Capitale, Île-de-France
Berlin, Bruxelles, Londres, Lyon, Milan, Munich, Paris, Rotterdam

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 004778
to stream PascalFrancis, to step Curation: 001925
to stream PascalFrancis, to step Checkpoint: 004464
to stream Main, to step Merge: 00B114
to stream Main, to step Curation: 00A513

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg</title>
<author><name sortKey="Zalcberg, John R" sort="Zalcberg, John R" uniqKey="Zalcberg J" first="John R." last="Zalcberg">John R. Zalcberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCullum Cancer Centre, Locked Bag 1, A'Beckett Street</s1>
<s2>Melbourne, Vic. 8006</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic. 8006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Erasmus Medical Centre</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Istituto per lo Studio e la Cura die Tumori</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Institut Guslare Roussy</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Haematology, Oncology and Tumorimmunology, HELlOS-Klinikum, Charité, Robert -Roessle -Klinik</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Medical Oncology, Hopilal E. Herriot & Centre L. Berard</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Klinikum Grosshadern</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>KKG Hyperthermie, GSF National Research Centre for Environment and Health</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>EORTC Data Centre</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brown, Michelle" sort="Brown, Michelle" uniqKey="Brown M" first="Michelle" last="Brown">Michelle Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>EORTC Data Centre</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Judson, Ian R" sort="Judson, Ian R" uniqKey="Judson I" first="Ian R." last="Judson">Ian R. Judson</name>
<affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Sarcoma Unit, Royal Marsden Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0400757</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0400757 INIST</idno>
<idno type="RBID">Pascal:05-0400757</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004778</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001925</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">004464</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004464</idno>
<idno type="wicri:doubleKey">0959-8049:2005:Zalcberg J:outcome:of:patients</idno>
<idno type="wicri:Area/Main/Merge">00B114</idno>
<idno type="wicri:Area/Main/Curation">00A513</idno>
<idno type="wicri:Area/Main/Exploration">00A513</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg</title>
<author><name sortKey="Zalcberg, John R" sort="Zalcberg, John R" uniqKey="Zalcberg J" first="John R." last="Zalcberg">John R. Zalcberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCullum Cancer Centre, Locked Bag 1, A'Beckett Street</s1>
<s2>Melbourne, Vic. 8006</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic. 8006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Erasmus Medical Centre</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Istituto per lo Studio e la Cura die Tumori</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Institut Guslare Roussy</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Haematology, Oncology and Tumorimmunology, HELlOS-Klinikum, Charité, Robert -Roessle -Klinik</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Medical Oncology, Hopilal E. Herriot & Centre L. Berard</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Klinikum Grosshadern</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>KKG Hyperthermie, GSF National Research Centre for Environment and Health</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>EORTC Data Centre</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brown, Michelle" sort="Brown, Michelle" uniqKey="Brown M" first="Michelle" last="Brown">Michelle Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>EORTC Data Centre</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Judson, Ian R" sort="Judson, Ian R" uniqKey="Judson I" first="Ian R." last="Judson">Ian R. Judson</name>
<affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Sarcoma Unit, Royal Marsden Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of cancer : (1990)</title>
<title level="j" type="abbreviated">Eur. j. cancer : (1990)</title>
<idno type="ISSN">0959-8049</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of cancer : (1990)</title>
<title level="j" type="abbreviated">Eur. j. cancer : (1990)</title>
<idno type="ISSN">0959-8049</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Crossing over</term>
<term>Daily dose</term>
<term>Enzyme inhibitor</term>
<term>Gastrointestinal stromal tumor</term>
<term>Gut</term>
<term>Human</term>
<term>Imatinib</term>
<term>Pharmacology</term>
<term>Prognosis</term>
<term>Protein-tyrosine kinase</term>
<term>Stroma</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Imatinib</term>
<term>Pronostic</term>
<term>Homme</term>
<term>Intestin</term>
<term>Stroma</term>
<term>Crossing over</term>
<term>Dose journalière</term>
<term>Protein-tyrosine kinase</term>
<term>Inhibiteur enzyme</term>
<term>Cancérologie</term>
<term>Pharmacologie</term>
<term>Anticancéreux</term>
<term>Tumeur stromale gastrointestinale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Pharmacologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumours (GIST) were randomised to receive 400 or 800 mg of imatinib daily. An increase in progression free survival (PFS) was demonstrated for patients randomised to the high-dose arm. Patients randomised to low-dose could cross-over to high-dose upon progression. We evaluated the feasibility, safety and efficacy of this policy. Of the 241 patients available for follow-up, 133 patients (55%) crossed over to high-dose imatinib according to the protocol. Of these patients, 92% had not had a prior dose reduction. The cumulative incidence of subsequent dose reductions after cross-over was 17% after six months with 51% discontinuing therapy without requiring a dose reduction. The extent of anaemia and fatigue increased significantly after cross-over, whilst neutropenia was less severe than during low-dose treatment. Objective responses after cross-over included three patients (2%) with a partial response and 36 (27%) with stable disease. The median PFS after cross-over was 81 days, although 18.1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Auvergne-Rhône-Alpes</li>
<li>Bavière</li>
<li>Berlin</li>
<li>District de Haute-Bavière</li>
<li>Grand Londres</li>
<li>Hollande-Méridionale</li>
<li>Lombardie</li>
<li>Rhône-Alpes</li>
<li>Région de Bruxelles-Capitale</li>
<li>Île-de-France</li>
</region>
<settlement><li>Berlin</li>
<li>Bruxelles</li>
<li>Londres</li>
<li>Lyon</li>
<li>Milan</li>
<li>Munich</li>
<li>Paris</li>
<li>Rotterdam</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Zalcberg, John R" sort="Zalcberg, John R" uniqKey="Zalcberg J" first="John R." last="Zalcberg">John R. Zalcberg</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name>
</region>
</country>
<country name="Italie"><region name="Lombardie"><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name>
</region>
<name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name>
</region>
<name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name>
<name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name>
</region>
<name sortKey="Brown, Michelle" sort="Brown, Michelle" uniqKey="Brown M" first="Michelle" last="Brown">Michelle Brown</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Judson, Ian R" sort="Judson, Ian R" uniqKey="Judson I" first="Ian R." last="Judson">Ian R. Judson</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A513 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A513 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0400757
   |texte=   Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri